Table 1

Demographics and clinico-biological features of patients with SLE

N=126
Female sex114 (90.5%)
Age, years46.6 (33.9, 58.7)
Time from SLE onset, months14.1 (7.2, 23.1)
Time from last flare, months2.4 (0.5, 6.2)
SLEDAI 2K2.0 (0.0, 4.0)
SLEDAI 2K>424 (19.0%)
At least one BILAG score ≥B20 (16.7%)
Hydroxychloroquine blood dosage, µg/L855.5 (641.0, 1,123.0)
Low complement C3 (<0.7 g/L)22 (17.5%)
Increased dsDNA binding (>30 IU/mL)63 (50.0%)
Detectable interferon alpha (>2 IU/mL)17 (14.8%)
Hydroxychloroquine106 (84.1%)
No corticosteroids56 (44.4%)
Corticosteroids≤10 mg/day57 (45.2%)
Corticosteroids>10 mg/day13 (10.3%)
Belimumab (intravenous, n=7, subcutaneous, n=8)15 (11.9%)
Mycophenolate mofetil24 (19.0%)
Azathioprine5 (4.0%)
Methotrexate20 (15.9%)
  • Qualitative variables are presented as n (%). Quantitative variables are presented as median (IQR).

  • .BILAG, British Isles Lupus Assessment Group; dsDNA, double-stranded DNA; SLE, systemic lupus erythematosus; SLEDAI, SLE Disease Activity Score.